No profile data available.
Harvard Apparatus Regenerative Technology Inc. (HRGN) is a healthcare company in the nutritional and natural health products industry, based in Holliston, United States, with about 8 full-time employees.
It reported revenue of $704,000 for fiscal year 2025, up 63.7% from fiscal year 2024, and net income of -$6.87 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $226,000, up 402.2% from a year before. Its market capitalization was $46.65 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease.
Harvard Apparatus Regenerative Technology reported $704,000 in revenue for fiscal year 2025, up 63.7% from $430,000 in fiscal year 2024. In Q1 2026 revenue was $226,000.
$46.65 million as of October 9, 2026.
Listed companies of a similar size in the same industry (nutritional and natural health products) include LifeVantage Corporation (LFVN), Goldenwell Biotech, Inc. (GWLL), Clene Inc. (CLNN), Zhong Yuan Bio-Technology Holdings Limited (ZHYBF).